Calidi Biotherapeutics (Calidi Biotherapeutics) COGS-to-Revenue : 0.00 (As of Mar. 2024)

View and export this data going back to 2023. Start your Free Trial

What is Calidi Biotherapeutics COGS-to-Revenue?

Calidi Biotherapeutics's Cost of Goods Sold for the three months ended in Mar. 2024 was $0.00 Mil. Its Revenue for the three months ended in Mar. 2024 was $0.00 Mil.

Calidi Biotherapeutics's COGS to Revenue for the three months ended in Mar. 2024 was 0.00.

Cost of Goods Sold is directly linked to profitability of the company through Gross Margin. Calidi Biotherapeutics's Gross Margin % for the three months ended in Mar. 2024 was N/A%.

Calidi Biotherapeutics COGS-to-Revenue Historical Data

The historical data trend for Calidi Biotherapeutics's COGS-to-Revenue can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Calidi Biotherapeutics COGS-to-Revenue Chart

Calidi Biotherapeutics Annual Data

Trend

Dec20

Dec21

Dec22

Dec23

COGS-to-Revenue

0.21

0.31

Calidi Biotherapeutics Quarterly Data
	Dec20	Sep21	Dec21	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24
COGS-to-Revenue	Get a 7-Day Free Trial					-	-	-	-	-

Calidi Biotherapeutics COGS-to-Revenue Calculation

Calidi Biotherapeutics's COGS to Revenue for the fiscal year that ended in Dec. 2023 is calculated as

COGS to Revenue	=	Cost of Goods Sold	/	Revenue
	=	0	/	0
	=

Calidi Biotherapeutics's COGS to Revenue for the quarter that ended in Mar. 2024 is calculated as

COGS to Revenue	=	Cost of Goods Sold	/	Revenue
	=	0	/	0
	=

Calidi Biotherapeutics (AMEX:CLDI) COGS-to-Revenue Explanation

Cost of Goods Sold is directly linked to profitability of the company through Gross Margin.

Calidi Biotherapeutics's Gross Margin % for the three months ended in Mar. 2024 is calculated as:

Gross Margin %	=	1	-	COGS to Revenue
	=	1	-	Cost of Goods Sold / Revenue
	=	1	-	0 / 0
	=	N/A %

A company that has a moat can usually maintain or even expand their Gross Margin. A company can increase its Gross Margin in two ways. It can increase the prices of the goods it sells and keeps its Cost of Goods Sold unchanged. Or it can keep the sales price unchanged and squeeze its suppliers to reduce the Cost of Goods Sold. Warren Buffett believes businesses with the power to raise prices have moats.

Calidi Biotherapeutics COGS-to-Revenue Related Terms

Thank you for viewing the detailed overview of Calidi Biotherapeutics's COGS-to-Revenue provided by GuruFocus.com. Please click on the following links to see related term pages.

Calidi Biotherapeutics (Calidi Biotherapeutics) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Calidi Biotherapeutics Inc (AMEX:CLDI) » Definitions » COGS-to-Revenue

Comparable Companies

Traded in Other Exchanges

N/A

Address

11011 North Torrey Pines Road, Suite 200, La Jolla, CA, USA, 92037

Website

https://www.calidibio.com

Calidi Biotherapeutics Inc is a clinical stage immuno-oncology company pioneering the development and commercialization of novel, potent and efficient stem cell-based platforms for delivery and potentiation of oncolytic viruses for the treatment of cancer.

Calidi Biotherapeutics (Calidi Biotherapeutics) Headlines

From GuruFocus

Calidi Biotherapeutics and Unusual Machines Interviews to Air on the RedChip Small Stocks, Big Mone(TM) Show on Bloomberg TV

By ACCESSWIRE • 05-17-2024